RAPGEF3 and neoplasm: The activation of cAMP-mediated PKA and EPAC signaling have been shown to promote tumor cell proliferation, survival, motility, adhesiveness and invasiveness in preclinical models of liver, lung, breast, brain and lymph cancers [35, 61].